WO2009017161A1 - 炎症性サイトカインの抑制剤 - Google Patents

炎症性サイトカインの抑制剤 Download PDF

Info

Publication number
WO2009017161A1
WO2009017161A1 PCT/JP2008/063676 JP2008063676W WO2009017161A1 WO 2009017161 A1 WO2009017161 A1 WO 2009017161A1 JP 2008063676 W JP2008063676 W JP 2008063676W WO 2009017161 A1 WO2009017161 A1 WO 2009017161A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
production
found
inflammatory
inhibition
Prior art date
Application number
PCT/JP2008/063676
Other languages
English (en)
French (fr)
Inventor
Tomoko Nakagawa
Yoshiro Kishi
Ichiro Yahara
Naomasa Yamamoto
Original Assignee
Medical And Biological Laboratories Co., Ltd.
Tokyo Metropolitan Organization For Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical And Biological Laboratories Co., Ltd., Tokyo Metropolitan Organization For Medical Research filed Critical Medical And Biological Laboratories Co., Ltd.
Publication of WO2009017161A1 publication Critical patent/WO2009017161A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

　ヒトCD３６を強制発現させたヒト培養細胞293Tでマウスを免疫し、得られた抗体のサイトカイン産生制御効果について検討したところ、PBMCによるIFNγ産生を単独で強く抑制する抗CD36抗体を見出した。他のサイトカイン産生に対する効果についても検討したところ、上記抗CD36抗体は代表的な炎症性サイトカインの産生を確実に抑制することが明らかになった。さらに上記抗CD36抗体に抗炎症性サイトカイン産生促進能があることを確認した。本発明の抗体は、主要な炎症性サイトカインの産生を抑制することにより、または抗炎症性サイトカインの産生を促進することにより、炎症性疾患治療を可能にする。
PCT/JP2008/063676 2007-07-30 2008-07-30 炎症性サイトカインの抑制剤 WO2009017161A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-197773 2007-07-30
JP2007197773A JP2010235447A (ja) 2007-07-30 2007-07-30 炎症性サイトカインの抑制剤

Publications (1)

Publication Number Publication Date
WO2009017161A1 true WO2009017161A1 (ja) 2009-02-05

Family

ID=40304391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063676 WO2009017161A1 (ja) 2007-07-30 2008-07-30 炎症性サイトカインの抑制剤

Country Status (2)

Country Link
JP (1) JP2010235447A (ja)
WO (1) WO2009017161A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2572730A1 (en) * 2010-05-20 2013-03-27 Toru Miyazaki Method for prevention or treatment of metabolic syndrome
WO2013096380A3 (en) * 2011-12-20 2013-08-22 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US10766953B2 (en) 2017-03-16 2020-09-08 Janssen Biotech, Inc. Anti-PHF-tau antibodies and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102404845B1 (ko) * 2018-10-16 2022-06-07 가톨릭대학교 산학협력단 인간화된 자가면역 질환 동물 모델 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026403A1 (en) * 1994-03-29 1995-10-05 Celltech Therapeutics Limited Antibodies against e-selectin
WO2002022150A2 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes antithrombin iii
WO2002032445A2 (de) * 2000-10-20 2002-04-25 Beate Kehrel Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus
WO2004068931A2 (en) * 2003-02-07 2004-08-19 Protein Design Labs Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
WO2006113909A2 (en) * 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026403A1 (en) * 1994-03-29 1995-10-05 Celltech Therapeutics Limited Antibodies against e-selectin
WO2002022150A2 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes antithrombin iii
WO2002032445A2 (de) * 2000-10-20 2002-04-25 Beate Kehrel Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus
WO2004068931A2 (en) * 2003-02-07 2004-08-19 Protein Design Labs Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
WO2006113909A2 (en) * 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOYEN V. ET AL.: "Thrombospondin 1 Is an Autocrine Negative Regulator of Human Dendritic Cell Activation", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 8, 2003, pages 1277 - 1283, XP002403013 *
IKEDA Y. ET AL.: "Aggregated Ursolic Acid, a Natural Triterpenoid, Induces IL-1beta Release from Murine Peritoneal Macrophages: Role of CD36", THE JOURNAL OF IMMUNOLOGY, vol. 178, no. 8, 15 April 2007 (2007-04-15), pages 4854 - 4864 *
MASLI S. ET AL.: "Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells", INTERNATIONAL IMMUNOLOGY, vol. 18, no. 5, 2006, pages 689 - 699 *
URBAN B.C. ET AL.: "A role for CD36 in the regulation of dendritic cell function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 15, 2001, pages 8750 - 8755 *
YEHUALASHET T. ET AL.: "A CD36 Synthetic Peptide Inhibits Bleomycin-Induced Pulmonary Inflammation and Connective Tissue Synthesis in the Rat", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 23, no. 2, 2000, pages 204 - 212 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2572730A1 (en) * 2010-05-20 2013-03-27 Toru Miyazaki Method for prevention or treatment of metabolic syndrome
EP2572730A4 (en) * 2010-05-20 2013-11-06 Toru Miyazaki PROCESS FOR PROPHYLAXIS OR TREATMENT OF METABOLIC SYNDROME
CN103648531A (zh) * 2010-05-20 2014-03-19 宫崎彻 用于预防或治疗代谢综合症的方法
WO2013096380A3 (en) * 2011-12-20 2013-08-22 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US9371376B2 (en) 2011-12-20 2016-06-21 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses
US9745371B2 (en) 2011-12-20 2017-08-29 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses
EA027975B1 (ru) * 2011-12-20 2017-09-29 Янссен Байотек, Инк. Анти-псф-тау-антитела и их применение
US10000559B2 (en) 2011-12-20 2018-06-19 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses
US10196440B2 (en) 2011-12-20 2019-02-05 Janssen Biotech, Inc. Anti-PHG-tau antibodies and their uses
US10766953B2 (en) 2017-03-16 2020-09-08 Janssen Biotech, Inc. Anti-PHF-tau antibodies and uses thereof
US11365244B2 (en) 2017-03-16 2022-06-21 Janssen Biotech, Inc. Anti-PHF-tau antibodies and uses thereof

Also Published As

Publication number Publication date
JP2010235447A (ja) 2010-10-21

Similar Documents

Publication Publication Date Title
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
WO2007126439A3 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
WO2010068794A3 (en) Hif inhibitors and use thereof
WO2010070675A3 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
MX365054B (es) Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en el tratamiento de enfermedades asociadas a una proliferacion celular no deseada.
CO6150099A2 (es) Agente de mejoramiento de fermentacion del rumen
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
MX354743B (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
UA105405C2 (ru) Гуманизированное антитело против человеческого il-22ra
GT200500266A (es) Nuevos derivados de pirimidina y su uso
MX2007011493A (es) Modalidades antiinflamatorias.
ATE520032T1 (de) Differentielle cytokinexpression bei einer menschlichen krebserkrankung
WO2011159693A3 (en) Oral treatment of digital ischemic lesions
WO2009017161A1 (ja) 炎症性サイトカインの抑制剤
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
DOP2016000076A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
UY33219A (es) Cetoenoles cíclicos para terapias
DE602007005041D1 (de) Verfahren zur Behandlung von Entzündungserkrankungen mit Maracujaextrakten

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791907

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791907

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP